FOSUN HEALTH Logo

Endometrial Cancer Causes

catalogue

Endometrial Cancer Causes

Endometrial Cancer Causes

Endometrial cancer has one of the clearest causal stories in oncology: the lining grows under estrogen, and cancer follows when estrogen acts for years without progesterone to check it. Weight, hormonal history and a small number of genes decide who sits in that hormonal environment the longest.

Unopposed estrogen — the central mechanism

The endometrium is a two-hormone system. Estrogen makes the lining grow; progesterone stops the growth and stabilises it. Every month the two alternate, and the lining is shed. Cancer becomes possible when estrogen acts for long stretches with no progesterone to counter it — the state clinicians call unopposed estrogen. The lining grows disordered, cells accumulate changes, and hyperplasia — then cancer — can follow.

Almost every established risk factor is a route into that state. Pregnancy floods the body with progesterone for months, which is why never having been pregnant raises risk. Late menopause extends the years of cycling. Estrogen-only hormone replacement — given without the opposing progestin — acts directly. Obesity manufactures estrogen inside fat tissue after the ovaries stop. Polycystic ovary syndrome withholds ovulation, and with it the progesterone surge. Seen this way, the risk list is not a list at all: it is one mechanism arriving by six doors.

The corollary matters for prevention: anything that restores the progesterone counterweight — pregnancy, the combined contraceptive pill, progestin-releasing intrauterine devices — lowers risk. The mechanism that explains the disease also explains its prevention.

Obesity and the hormonal pathway

Obesity deserves its own section because it is the strongest modifiable risk factor for this disease, and the mechanism is concrete rather than statistical. After menopause the ovaries stop making estrogen — but fat tissue contains the enzyme aromatase, which converts androgens from the adrenal glands into estrogen. More fat tissue means more estrogen, produced continuously, with no progesterone anywhere near it. The postmenopausal woman with obesity is living inside the unopposed-estrogen state by default.

The association is strong and dose-dependent: risk rises with each increment of weight, and weight loss after menopause measurably lowers the estrogen level. This is also why endometrial cancer incidence tracks the obesity curve in country after country — and why the disease, though commonest in the sixties and seventies, is appearing at younger ages where obesity is common.

Two honest framing points. First, most women with obesity do not develop endometrial cancer — the mechanism raises probability, it does not determine it. Second, the message is not blame but leverage: weight is the one input on the whole risk list a patient can move, and it moves the risk of several other cancers at the same time.

Lynch syndrome and family history

Around 5% of endometrial cancers arise in Lynch syndrome, an inherited condition in which one copy of a DNA mismatch-repair gene does not work from birth. Cells with a single working copy manage — until the second copy is damaged by chance, after which repair errors accumulate and cancers follow. Lynch syndrome raises the risk of colon cancer above all, and endometrial cancer is its commonest manifestation in women — often arriving before the colon does.

The practical implications are specific. Women with Lynch syndrome are offered annual surveillance of the lining from age 35, and many consider risk-reducing hysterectomy once childbearing is complete — decisions made with a genetics team, not improvised. And because the condition is inherited, every diagnosis of endometrial cancer in a woman under 60, and any case with colon cancer in the family, is a prompt for mismatch-repair testing of the tumour — the same test that already guides immunotherapy. Finding Lynch syndrome changes the surveillance plan for the patient herself, and for her children and siblings.

Tamoxifen and hormone therapy

Tamoxifen — the hormone tablet taken for years after breast cancer — blocks estrogen receptors in breast tissue but acts mildly estrogenic on the endometrium. It raises the risk of endometrial cancer and of polyps, in a dose- and duration-dependent way. The risk is real but modest, and for most women the benefit against breast cancer recurrence far outweighs it — the answer is not to stop tamoxifen but to take its gynaecological side seriously: any abnormal bleeding during tamoxifen gets the same ultrasound-and-biopsy work-up as any postmenopausal bleeding, without exception. Routine extra screening beyond symptom-triggered assessment is not recommended and is not a substitute for reporting bleeding.

Hormone replacement therapy divides by composition. Estrogen-only therapy — appropriate only for women who have had a hysterectomy, since they have no uterus to protect — raises endometrial cancer risk precisely because it is unopposed. Combined therapy, estrogen with a progestin, restores the counterweight and does not carry the same risk. Women on either regimen should still report bleeding promptly: therapy explains some bleeding, but never all of it.

What does not cause it

Several beliefs circulate that the evidence does not support:

  • Infection — no infection causes endometrial cancer. This distinguishes it from cervical cancer (HPV-driven); the two diseases share an organ region but nothing else. It is not contagious and cannot be caught or transmitted.
  • Fertility treatment — ovulation-inducing drugs have been studied extensively; the current evidence does not show them raising endometrial cancer risk independent of the infertility itself.
  • Intrauterine devices — the progestin-releasing device lowers endometrial cancer risk; copper devices show no increase.
  • Stress or a blow to the body — trauma and psychological stress have no established role in causing this cancer.
  • A single late or heavy period — one anomalous cycle, particularly in perimenopause, is overwhelmingly hormonal and not a cancer signal by itself; it is the pattern and persistence that matter.

Where beliefs like these delay care, they cost exactly what this cancer rewards — the early weeks in which a symptom leads to an ultrasound. The evidence-based list is short: estrogen exposure, weight, age, and genes.

Who is at higher risk

Bringing the sections together, the risk profile in plain terms — the disease is commonest after 50, and risk rises with any combination of:

  • Obesity, especially after menopause
  • Never having been pregnant
  • Late menopause (after 55) or early first period
  • Polycystic ovary syndrome or type 2 diabetes
  • Estrogen-only hormone therapy (with the uterus in place) or long-term tamoxifen
  • A family history of colon or endometrial cancer, or known Lynch syndrome
  • Previous hyperplasia with atypia of the lining

Two groups deserve a standing arrangement rather than symptom-triggered care. Women with Lynch syndrome should have a genetics-led surveillance plan in place. And women with long-standing anovulation from polycystic ovary syndrome should make sure their irregular bleeding is actually investigated once, with an ultrasound, rather than accepted as their normal — the hormonal pattern that makes cycles irregular is the same one that lets the lining grow unopposed.

Frequently Asked Questions

Is endometrial cancer hereditary?

In a minority of cases — about 5% — yes, through Lynch syndrome, an inherited DNA repair condition that also raises colon cancer risk. Testing the tumour's mismatch-repair proteins, a standard part of modern pathology, identifies most carriers, and a blood test confirms the diagnosis. A family history of colon cancer diagnosed young, or endometrial cancer across generations, is the pattern that triggers testing. For the other 95%, the disease follows the estrogen-and-weight pathway and is not passed on.

Does the contraceptive pill raise or lower risk?

Lower it. The combined pill supplies the progesterone counterweight that unopposed estrogen lacks, and years of use measurably reduce endometrial cancer risk, with protection persisting for years after stopping. The progestin-releasing intrauterine device acts the same way locally. This is one of the better-established protective effects in gynaecology, and it is worth knowing when weighing the pill's other considerations.

I take tamoxifen — should I have extra screening?

No routine extra screening is recommended, and symptom-triggered assessment is what actually works: any bleeding while on tamoxifen gets an ultrasound and, if the lining is thickened, a biopsy, without waiting and without exception. Routine scans of an asymptomatic lining produce polyps and false alarms more than they produce earlier diagnoses. The tamoxifen benefit against breast cancer recurrence stands for the great majority of women; the endometrial risk is managed by taking bleeding seriously, not by stopping the tablet.

Does diabetes raise the risk independently?

Yes — type 2 diabetes is associated with higher endometrial cancer risk even accounting for weight, and the two travel together: obesity drives insulin resistance, and the insulin-and-estrogen environment acts on the same lining. For women with both, the practical implications compound rather than compete: weight management addresses both pathways at once, and irregular bleeding in a woman with diabetes deserves an ultrasound sooner rather than later.

Know where you stand on risk

Recognise yourself in the risk list — or carry Lynch syndrome in the family? Upload your history and any previous biopsy results, and our gynaecological team will tell you what testing and surveillance are worth arranging, in writing within 48 hours.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*